Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure.
The study's primary endpoint was stabilization or improvement in cardiac functional capacity as measured by Peak VO2 in patients treated with AT-001 1500mg twice daily (BID) compared to placebo.
Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday.
Here are some other stocks moving in today's mid-day session.
Gainers
- Ainos, Inc.(NASDAQ: AIMD) jumped 112.6% to $3.6805 after falling more than 12% on Thursday.
- Revelstone Capital Acquisition Corp. (NASDAQ: RCAC) shares climbed 89.6% to $10.71. Revelstone Capital Acquisition cancelled special meeting to approve business combination with Set Jet, Inc.
- Banzai International, Inc. (NASDAQ: BNZI) surged 74% to $2.92. Banzai International signed a non-binding letter of intent to acquire IGLeads, a cutting-edge automated lead generation platform.
- Safe and Green Development Corporation (NASDAQ: SGD) shares rose 56.5% to $2.1307. Safe And Green Development recently issued an update on LOI for acquisition of Xene AI Software platform.
- NexImmune, Inc. (NASDAQ: NEXI) gained 30% to $7.67
- Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose climbed 27.8% to $0.78 after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
- Polished.com Inc. (NYSE: POL) gained 27.2% to $8.05.
- Swvl Holdings Corp. (NASDAQ: SWVL) gained 27.2% to $2.90.
- PolyPid Ltd. (NASDAQ: PYPD) gained 25% to $8.44. PolyPid announced $16.2 million private placement of 3,371,312 shares at $4.81 per share.
- AxoGen, Inc. (NASDAQ: AXGN) jumped 20.4% to $8.13 as the company reported preliminary unaudited revenue for fourth quarter and full-year 2023. The company also said President and Chief Executive Officer Karen Zaderej plans to retire from the Company by Jan. 2025.
- Aurora Mobile Limited (NASDAQ: JG) jumped 19.2% to $3.79.
- Kura Sushi USA, Inc. (NASDAQ: KRUS) rose 15.7% to $86.31 following first-quarter results.
- The Greenbrier Companies, Inc. (NYSE: GBX) gained 13.8% to $50.50 following upbeat earnings.
- Peloton Interactive, Inc. (NASDAQ: PTON) rose 13.1% to $6.93.
- Pinstripes Holdings Inc. (NYSE: PNST) shares gained 12.4% to $5.92 after dipping over 35% on Thursday.
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) rose 12.4% to $2.53.
- Elanco Animal Health Incorporated (NYSE: ELAN) gained 8% to $15.72. Stifel analyst Jonathan Block upgraded Elanco Animal Health from Hold to Buy and raised the price target from $13 to $20.
- Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares rose 7.2% to $0.3212 after falling around 5% on Thursday. Intelligent Bio Solutions recently received National Association of Testing Authorities accreditation for its Intelligent Fingerprinting Drug Screening Solution.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- agilon health, inc. (NYSE: AGL) tumbled 35.1% to $7.84 after the company lowered its 2023 financial outlook.
- Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares fell 33.7% to $0.2266. Avenue Therapeutics shares jumped over 94% on Thursday after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol.
- Medical Properties Trust, Inc. (NYSE: MPW) fell 30.6% to $3.4699 after it disclosed plans to reduce its exposure to tenant Steward Health Care System. Keybanc analyst Austin Wurschmidt downgraded Medical Properties Trust from Overweight to Sector Weight.
- AngioDynamics, Inc. (NASDAQ: ANGO) dipped 22.6% to $6.00 after the company lowered its FY24 guidance.
- Lucy Scientific Discovery Inc. (NASDAQ: LSDI) fell 22% to $0.1949.
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) fell 19.1% to $8.77. Voyager Therapeutics priced its public offering of 7,777,778 common shares at $9 per share.
- Verb Technology Company, Inc. (NASDAQ: VERB) shares fell 17.4% to $0.1340. On Dec. 29, Verb Technology Company entered into a securities purchase agreement with Streeterville Capital where company sold and investor purchased 3,000 shares of the company's newly designated non-convertible Series C preferred stock for $3 million.
- KORE Group Holdings, Inc. (NYSE: KORE) shares fell 14.8% to $1.04 after jumping over 60% on Thursday.
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) shares declined 14.1% to $2.9050. Allogene Therapeutics and Foresight Diagnostics disclosed a partnership to develop MRD-based in-vitro diagnostic for use in ALPHA3, the first pivotal trial for frontline consolidation in large B-cell lymphoma. JMP Securities and Guggenheim downgraded the stock.
- Omega Therapeutics, Inc. (NASDAQ: OMGA) declined 13.8% to $4.58.
- CISO Global Inc. (NASDAQ: CISO) shares fell 13.7% to $0.0901. CISO Global said the Nasdaq has determined to delist securities from Nasdaq.
- Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) shares fell 13.4% to $14.81 after announcing pricing of public offering of common stock.
- Smart for Life, Inc. (NASDAQ: SMFL) shares fell 12.3% to $1.6408 after jumping around 15% on Thursday.
- Exscientia plc (NASDAQ: EXAI) fell 10.8% to $5.84. B of A Securities analyst Michael Ryskin downgraded Exscientia from Buy to Neutral and lowered the price target from $11 to $9.
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) tumbled 9.1% to $5.90.
- Sabine Royalty Trust (NYSE: SBR) fell 8.7% to $63.02.
- Dyne Therapeutics, Inc. (NASDAQ: DYN) shares fell 8% to $17.84. Dyne Therapeutics priced its $300 million public offering of 17.15 million common stock at $17.50 per share.
- Immunocore Holdings plc (NASDAQ: IMCR) dipped 7.3% to $64.61. Immunocore announced strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation.
- Theravance Biopharma, Inc. (NASDAQ: TBPH) shares fell 6.6% to $10.76 after the company announced results from Phase 4 YUPELRI PIFR-2 study. The company said study did not show a statistically significant difference between yupelri and spiriva handihaler on primary endpoint.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.